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COPD and GOLD Stage I
To the Editor:
An abnormally low FEV 1 /FVC ratio is universally accepted as indicative of obstructive lung disease. Clearly, the choice of cutoff to defi ne abnormality is important. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) group set the lower limit of normal (LLN) at 0.7 irrespective of age, defi ning GOLD COPD stage I as FEV 1 /FVC below 0.7 and FEV 1 above 80% predicted. 1 In a recent issue of CHEST (January 2012), Mannino and Diaz-Guzman 2 argue that patients in GOLD stage I are at increased risk of premature death from respiratory causes.
As shown in many publications, the 0.7 cutoff is too simplistic. After age 45, the LLN based on the fi fth centile of the FEV 1 /FVC ratio falls progressively below 0.7, meaning that the 0.7 cutoff identifi es many older patients above the LLN as false positives. Several studies have tried to validate GOLD stage I for identifying obstructive lung disease:
In asymptomatic subjects, it was neither associated with pre-• mature death 3 , 4 nor with an abnormal decline in FEV 1 , respiratory care use, or quality of life compared with a reference group. 5 It was not associated with premature death or respiratory • symptoms. 6 The adjusted hazard ratio for premature death was not • signifi cant. 7 Now, Mannino and Diaz-Guzman • 2 state that subjects in GOLD stage I who are above the LLN are at increased risk of premature death from respiratory causes. They fail to present adjusted hazard ratios for respiratory death. Hence, their conclusion lacks evidence; it also contradicts a previous study where the same analysis was done on the same data. 6 Thus, there is no evidence to support the use of GOLD stage I. Conversely, there is considerable evidence in favor of the LLN:
Only GOLD stage I with FEV • 1 /FVC below the LLN was associated with increased risk of death. 6 , 7 The use of the LLN for both FEV • 1 /FVC and FEV 1 , rather than a fi xed ratio and 80% predicted, identifi ed persons with an increased risk of death and prevalence of respiratory symptoms. 8 "After correction for potential confounders, only severe • COPD as defi ned by the BTS [British Thoracic Society] criteria was still associated with mortality." 9 We conclude that GOLD stage I is not associated with respiratory disease or death from respiratory causes unless FEV 1 /FVC is below the LLN. Incorrectly labeling subjects as having COPD by the GOLD criteria has detrimental consequences for the individual and family: It incurs high costs for society, and it hampers research into the causes of COPD and its treatment. The mystery is why the GOLD group continues to encourage its use . 
Contemporary Aminophylline Use for Status Asthmaticus in Pediatric ICUs
To the Editor:
Methylxanthines, including aminophylline and theophylline, have long played a signifi cant role in the treatment of pediatric acute asthma exacerbations. 1 Current expert guidelines recommend against aminophylline use for acute exacerbations because of the availability of selective b 2 -agonists such as albuterol, in addition to the narrow therapeutic index and the limited evidence for effi cacy of this drug. 1 -3 We sought to examine whether aminophylline continues to be used for status asthmaticus in pediatric ICUs (PICUs) by surveying PICU fellowship training programs.
We administered an e-mail-based questionnaire to 58 pediatric critical care fellowship directors in the United States representing a geographic sampling of small to large training programs. The survey consisted of 15 questions pertaining to the use of www.chestpubs.org aminophylline for status asthmaticus in the PICU (e-Appendix 1 ). The survey was distributed three times at 3-week intervals, and responses were anonymous. The study protocol and questionnaire were approved by the Vanderbilt University institutional review board (protocol No. 101136).
Responses were received from 39 of the surveyed program directors (67%). Twenty-three of those responses (59%) indicated that their PICUs currently use aminophylline for status asthmaticus. All positive respondents (100%) indicated that aminophylline use was based on clinical judgment rather than institutional protocol. Twenty of those using aminophylline (87%) stated that the medication was used only when other treatments had failed. Fourteen of the respondents (61%) whose institution used aminophylline identifi ed a therapeutic range for serum aminophylline levels. Six of these respondents (43%) identifi ed a therapeutic serum level of 10 to 20 m g/mL for aminophylline, the generally accepted therapeutic range. 4 There was variation in the reporting of both the minimal effective serum level (mean, 10 m g/mL; range, 5-15 m g/mL) and the toxic serum level (mean, 17.9 m g/mL; range, 10-25 m g/mL ).
Aminophylline continues to be used to treat status asthmaticus in PICUs, as determined by surveying fellowship training programs, despite limited evidence for effi cacy and expert guidelines recommending against its use for this purpose. If pediatric critical care physicians are to continue to use this drug, further studies are recommended and warranted to assess its effi cacy and safety. What Is the Pulmonary Rehabilitation Adapted Index of Self-Effi cacy Tool Actually Measuring?
We read with great interest the study by Vincent et al 1 recently published in CHEST (December 2011). We commend the authors for expanding the fi eld of self-effi cacy research for patients with COPD.
The Pulmonary Rehabilitation Adapted Index of Self-Effi cacy (PRAISE) tool contains 15 items, 10 assessing "general" self-effi cacy and fi ve assessing self-effi cacy specifi c to pulmonary rehabilitation (PR). The PRAISE tool showed a signifi cant response following PR; however, given the task-specifi c nature of the self-effi cacy construct, 2 , 3 we wonder if the increase in self-effi cacy was predominantly related to an improvement in the PR-specifi c items rather than in general self-effi cacy. We believe the article would have benefi tted from an analysis of individual item performance. If the improvement had been related to PR items only, it may have allowed for abbreviation of the tool. On the other hand, improvement of the general self-effi cacy items would suggest that PR benefi ted areas other than mastery of exercise, such as problem-solving and coping skills (critical aspects of behavioral change for self-management), even though changes in behavior following PR were not measured in this study.
Our interest in exploring the task-specifi c nature of the selfeffi cacy construct emerges from our own research. We recently completed the validation of two physical activity questionnaires in patients with COPD compared with objectively measured physical activity, and we included self-effi cacy as a possible covariate. We found that general self-effi cacy (Stanford Self-Effi cacy for Managing Chronic Disease 6-Item Scale) was not significantly associated with physical activity. If the proposed analysis confi rms that the PR-related items were responsible for the measured improvement, then our results are congruent and collectively highlight the importance of creating task-specifi c selfeffi cacy tools.
We agree with the authors that self-effi cacy for activities prescribed in PR may contribute to a critical behavior: adherence to the PR program. Regrettably, the pre-PR PRAISE score showed no association with completion of the program. There were, however, correlations between the change in the Chronic Respiratory Questionnaire emotion and mastery domains (which may represent improved behaviors) and the change in the PRAISE score following PR. We believe a mediation analysis, as described previously, 4 , 5 is the most appropriate way to determine if the change in self-effi cacy is responsible for the improvements in these domains rather than the direct effect of the PR itself.
We believe the proposed analyses will help determine what the PRAISE tool is actually measuring. We are convinced that additional research aimed at understanding the behavioral aspects of PR is critically needed.
